Gink­go Bioworks re­sizes the de­f­i­n­i­tion of go­ing big in biotech, rais­ing $2.5B in a record SPAC deal that weighs in with a whop­ping $15B-plus val­u­a­tion

Gink­go Bioworks ex­ecs al­ways thought big. But to­day should re­de­fine just how big an up­start biotech play­er can dream.

In the largest SPAC deal to clear the hur­dles to NYSE, the biotech that en­vi­sioned every­thing from re­mak­ing syn­thet­ic meat to a whole new ap­proach to de­vel­op­ing drugs has joined forces with one of the biggest dis­rup­tors in biotech to slam the Richter scale on deal­mak­ing.

Soon af­ter be­com­ing the dar­ling of the VC crew and clear­ing the bar on a $4 bil­lion val­u­a­tion, Gink­go — a syn­thet­ic biotech play­er out to re­pro­gram cells with in­dus­tri­al ef­fi­cien­cy — has now struck a deal to go pub­lic in the lat­est leviathan SPAC that sets its pre-mon­ey val­u­a­tion at $15 bil­lion. In one swift vault, Gink­go will com­bine with Har­ry Sloan’s Soar­ing Ea­gle Ac­qui­si­tion Corp. and leap in­to the pub­lic mar­kets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER